alexa
Reach Us +44-1904-929220
Genetic Polymorphisms And Survival Times In Colorectal Cancer Patients | 8901
ISSN-2155-9929

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Genetic polymorphisms and survival times in colorectal cancer patients

4th International Conference on Biomarkers & Clinical Research

Sevtap Savas

ScientificTracks Abstracts: J Mol Biomark Diagn

DOI: 10.4172/2155-9929.S1.017

Abstract
The 5-year survival rate for colorectal cancer is ~60-65% in North America. Stage of the disease and age of the patient at the time of diagnosis are well-known prognostic indicators. However, in addition to these factors, there may be others, such as genetic factors that may modify the patient survival. To test this hypothesis, in collaboration with the Newfoundland Colorectal Cancer Registry (NFCCR), our laboratory focuses on investigating the correlations of genetic polymorphisms with clinical outcome in colorectal cancer patients. So far, our results showed that several genetic polymorphisms were associated with survival times of colorectal cancer patients. For example, a polymorphism in the MTHFR gene was associated with overall survival (OS) in two separate colorectal cancer cohorts (Negandhi et al. in preparation). The MTHFR protein has biological roles in metabolism of folate as well as 5-fluorouracil, a drug commonly used in treatment of colorectal cancer. Associations of polymorphisms in the SLC6A4 gene with OS were also detected. This gene codes for the serotonin transporter protein that may have roles in systemic inflammation and risk of depression. We also found the associations of polymorphisms from two genes regulating the cellular response to hypoxic conditions with OS.We are currently in the process of replicating these positive associations in additional colorectal cancer patients. Once our findings are replicated, our future studies will focus on investigating the biology behind these polymorphisms and their effect on survival of colorectal cancer patients.
Biography
Sevtap Savas obtained her Ph.D. in Molecular Biology and Genetics in 1999 from the Bogazici University, Turkey. She then trained as a post- doctoral fellow and research associate in Louisiana State University (USA), Mount Sinai Hospital Research Institute (Canada) and Princess Margaret Hospital/Ontario Cancer Institute (Canada). She has been an Assistant Professor at Discipline of Genetics, Memorial University of Newfoundland (Canada) since 2008. Her research program currently focuses on genetic prognostic studies in colorectal cancer and development of public databases using genetic, epidemiological, biostatistical and computational approaches. She also serves as a reviewer and editorial board member for several scientific journals
Relevant Topics
Top